Abstract
The CNS drug market presents significant profit opportunities, but also
carries high risks for companies aiming to achieve blockbuster status;
pipelines based on novel molecular targets to treat underlying disease promise
to transform the treatment of psychiatric and neurological diseases, however
research and development of these drugs requires an innovative approach to
ensure investment is maximized. ' Innovations in CNS: Novel therapeutics and
future R&D strategies' assesses novel treatments in development for major CNS
disorders, comparing them with existing medications in terms of unmet need and
forecasting their success in the commercial market. This report will enable
you to understand the research tactics of your competitors and develop winning
strategies for future growth in the lucrative CNS market. The report provides
a survey of the pipelines of all of the major players in the CNS area.
Detailed company profiles featured in the report include: AstraZeneca,
GlaxoSmithKline, Merck &Co, Pfizer, and Sanofi-Aventis. Use this report to
understand the factors that will ensure your product pipeline achieves
clinical and commercial success and analyze the product pipelines of the
leading companies in the CNS market.
| 
View Cart
